Tracking how well cancer immunotherapy is working using DNA from blood samples
Monitoring Immunotherapy Response via Gene Silencing Landscapes in Cell-Free DNA
This study is looking at how we can better track how well immunotherapy is working for people with non-small cell lung cancer by checking for changes in cancer DNA found in their blood, which could help doctors make more personalized treatment choices.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Binary Genomics, INC. NIH-funded |
| Lab location | 1 site (Phoenix, UNITED STATES) |
| Project ID | NIH-10922080 on NIH RePORTER |
What this research studies
This research focuses on improving the monitoring of immunotherapy responses in patients with non-small cell lung cancer by analyzing circulating tumor DNA (ctDNA) from blood samples. The approach utilizes a novel assay that detects epigenetic changes in cancer cell genomes, which can provide insights into treatment efficacy without the need for complex and costly tumor profiling. By identifying early changes in ctDNA levels, the research aims to better predict which patients will benefit from immunotherapy, potentially leading to more personalized treatment decisions.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who are undergoing immunotherapy treatment.
Not a fit: Patients with cancers that do not involve circulating tumor DNA or those not receiving immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate monitoring of immunotherapy responses, helping to identify effective treatments for patients with non-small cell lung cancer.
How similar studies have performed: Previous studies have shown promise in using ctDNA as a biomarker for monitoring cancer treatment, indicating that this approach has potential for success.
Where this research is happening
Phoenix, UNITED STATES
- Binary Genomics, INC. — Phoenix, United States (Active)
Researchers
- Principal investigator: Barrett, Michael T — Binary Genomics, INC.
- Study coordinator: Barrett, Michael T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.